Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Pomalidomide + Dexamethasone in Newly Diagnosed AL Amyloidosis
NCT06455748Recruiting
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Open-label, single-arm trial of pomalidomide in amyloid light chain amyloidosis. Primary endpoint: Hematologic Overall Remission Rate at 1 year. Started Mar 2024; status: recruiting.
02
Drugs
pomalidomide
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT06455748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455748.